Keith L. Ligon

Sep 4, 2024 | nature.com | Xiyue Wang |Junhan Zhao |Ruijiang Li |Nancy Lin |Keith L. Ligon |Sabina Signoretti | +3 more

AbstractHistopathology image evaluation is indispensable for cancer diagnoses and subtype classification. Standard artificial intelligence methods for histopathology image analyses have focused on optimizing specialized models for each diagnostic task1,2. Although such methods have achieved some success, they often have limited generalizability to images generated by different digitization protocols or samples collected from different populations3.

Dec 4, 2023 | nature.com | Shahabbedin Sotudian |Xintao Qiu |Renee Maria Saliby |Rong Li |Cindy H Chau |James A. DeCaprio | +14 more

Correction to: Nature Medicine https://doi.org/10.1038/s41591-023-02605-z, published online 21 October 2023. This article was originally published under a standard Springer Nature license (© The Author(s), under exclusive licence to Springer Nature America, Inc.); it is now available as an open-access paper under a Creative Commons Attribution 4.0 International license, © The Author(s). The error has been corrected in the HTML and PDF versions of the article.

Oct 21, 2023 | nature.com | Xintao Qiu |Renee Maria Saliby |Rong Li |Cindy H Chau |James A. DeCaprio |William D Figg | +14 more

AbstractAlthough circulating tumor DNA (ctDNA) assays are increasingly used to inform clinical decisions in cancer care, they have limited ability to identify the transcriptional programs that govern cancer phenotypes and their dynamic changes during the course of disease. To address these limitations, we developed a method for comprehensive epigenomic profiling of cancer from 1 ml of patient plasma.

Jul 7, 2023 | cell.com | David Meredith |Keith L. Ligon |Jeffrey Golden

Highlights•We established the Cryosection Histopathology Assessment and Review Machine (CHARM)•CHARM predicted IDH mutation and 2021 WHO classification of glioma using cryosections•CHARM provided quantitative evidence supporting the reclassification of astrocytoma•CHARM facilitated real-time cryosection diagnoses and can be extended to other cancersContext and significanceReal-time pathology diagnosis of tissue samples is crucial for the optimal treatment of brain cancers.

May 20, 2023 | nature.com | Keith L. Ligon

AbstractMalignant pleural mesothelioma (MPM) has relatively ineffective first/second-line therapy for advanced disease and only 18% five-year survival for early disease. Drug-induced mitochondrial priming measured by dynamic BH3 profiling identifies efficacious drugs in multiple disease settings. We use high throughput dynamic BH3 profiling (HTDBP) to identify drug combinations that prime primary MPM cells derived from patient tumors, which also prime patient derived xenograft (PDX) models.